Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 72% CR at any point in time.

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Apr 30, 2023 2:58pm

145 Views

Post# 35421771

RE:RE:72% CR at any point in time.

I get these numbers, and I agree. Though I think the 12 undertreated do represent an unfair, slightly, representation of 1433 for NMIBC in this Phase 2. I don't think all of the undertreated would have been CR if treated properly, but 63% or so might have been. Certainly at 90 days. So I would add them back in at that % to come up with new percentages for 90 days at least...

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China